An Emerging Model for Cancer Development from a Tumor Microenvironment Perspective in Mice and Humans.
Cancer associated fibroblast (CAF)
Cancer development
Chemokines
Cytokines
Ductal carcinoma in situ (DCIS)
Epithelial-to-mesenchymal transition (EMT)
Lymphocytic infiltration
Malignant pleural mesothelioma (MPN)
Metastasis
Myeloid-derived suppressor cell (MDSC)
Natural killer cell (NK)
Pleural effusion
Tumor associated macrophage (TAM)
Tumor microenvironment
Journal
Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
8
2
2020
pubmed:
8
2
2020
medline:
18
2
2020
Statut:
ppublish
Résumé
In the past, cancer development was studied in terms of genetic mutations acquired in cancer cells at each stage of the development. We present an emerging model for cancer development in which the tumor microenvironment (TME) plays an integral part. In this model, the tumor development is initiated by a slowly growing nearly homogeneous colony of cancer cells that can evade detection by the cell's innate mechanism of immunity such as natural killer (NK) cells (first stage; colonization). Subsequently, the colony develops into a tumor filled with lymphocytes and stromal cells, releasing pro-inflammatory cytokines, growth factors, and chemokines (second stage; lymphocyte infiltration). Cancer progression proceeds to a well-vesiculated silent tumor releasing no inflammatory signal, being nearly devoid of lymphocytes (third stage; silenced). Eventually some cancer cells within a tumor undertake epithelial-to-mesenchymal transition (EMT), which leads to cancer metastasis (fourth stage; EMT). If a circulating metastasized cancer cell finds a niche in a new tissue and evades detection by NK cells, it can establish a new colony in which very few stromal cells are present (fifth stage; metastasis), which is much like a colony at the first stage of development. At every stage, cancer cells influence their own TME, and in turn, the TME influences the cancer cells contained within, either by direct interaction between cancer cells and stromal cells or through exchange of cytokines. In this article, we examine clinical findings and animal experiments pertaining to this paradigm-shifting model and consider if, indeed, some aspects of cancer development are governed solely by the TME.
Identifiants
pubmed: 32030645
doi: 10.1007/978-3-030-35727-6_2
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
19-29Subventions
Organisme : NIGMS NIH HHS
ID : R24 GM137200
Pays : United States
Références
Stratton MR (2011) Exploring the genomes of cancer cells: progress and promise. Science 331(March):1553–1558. https://doi.org/10.1126/science.1204040
doi: 10.1126/science.1204040
pubmed: 21436442
Marcus A, Gowen BG, Thompson TW et al (2014) Recognition of tumors by innate immune system and natural killer cells. Adv Immunol 122:91–128 https://doi.org/10.1016/B978-0-12-800267-4.00003-1
Burstein HJ, Polyak K et al (2004) Ductal carcinoma in situ of the breast. N Engl J Med 350:1430–1441
doi: 10.1056/NEJMra031301
Yamaguchi R, Perkins G (2018) Animal models for studying tumor microenvironment (TME) and resistance to lymphocytic infiltration. Cancer Biol Ther 18:1–10. https://doi.org/10.1080/15384047.2018.1470722
doi: 10.1080/15384047.2018.1470722
Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348(6230):74–80
doi: 10.1126/science.aaa6204
Yeung KT, Yang J (2017) Epithelial–mesenchymal transition in tumor metastasis. Mol Oncol 11:28–39. https://doi.org/10.1002/1878-0261.12017
doi: 10.1002/1878-0261.12017
pubmed: 28085222
Labelle M, Begum S, Hynes RO (2011) Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20:576–590. https://doi.org/10.1016/j.ccr.2011.09.009
doi: 10.1016/j.ccr.2011.09.009
pubmed: 22094253
pmcid: 3487108
Hong Y, Fang F, Zhang Q (2016) Circulating tumor cell clusters: what we know and what we expect (review). Int J Oncol 49:2206–2216. https://doi.org/10.3892/ijo.2016.3747
doi: 10.3892/ijo.2016.3747
pubmed: 27779656
pmcid: 5117994
Harlin H, Meng Y, Peterson AC et al (2009) Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 69(7):3077–3086. https://doi.org/10.1158/0008-5472.CAN-08-2281
doi: 10.1158/0008-5472.CAN-08-2281
pubmed: 19293190
Gabrilovich DI (2017) Myeloid-derived suppressor cells. Cancer Immunol Res 5(1):3–9. https://doi.org/10.1158/2326-6066.CIR-16-0297
doi: 10.1158/2326-6066.CIR-16-0297
pubmed: 28052991
pmcid: 5426480
Malladi S, Macalinao D, Jin X et al (2016) Metastatic latency and immune evasion through autocrine inhibition of WNT article metastatic latency and immune evasion through autocrine inhibition of WNT. Cell 165:45–60. https://doi.org/10.1016/j.cell.2016.02.025
doi: 10.1016/j.cell.2016.02.025
pubmed: 27015306
pmcid: 4808520
Tabbekh M, Franciszkiewicz K (2018) Rescue of tumor-infiltrating lymphocytes from activation-induced cell death enhances the antitumor CTL response in CD5-deficient mice. J Immunol 187:102–109. https://doi.org/10.4049/jimmunol.1004145
doi: 10.4049/jimmunol.1004145
Zhou R, He P, Ren Y et al (2007) Myeloid suppressor cell-associated immune dysfunction in CSA1M fibrosarcoma tumor-bearing mice. Cancer Sci 98(6):882–889. https://doi.org/10.1111/j.1349-7006.2007.00465.x
doi: 10.1111/j.1349-7006.2007.00465.x
pubmed: 17433038
Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ (2012) Tumor-derived granulocytes-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21(6):822–835. https://doi.org/10.1016/j.ccr.2012.04.025
doi: 10.1016/j.ccr.2012.04.025
pubmed: 22698406
pmcid: 3575028
Pylayeva-gupta Y, Lee KE, Hajdu CH, Miller G, Bar-sagi D (2012) Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21(6):836–847. https://doi.org/10.1016/j.ccr.2012.04.024
doi: 10.1016/j.ccr.2012.04.024
pubmed: 22698407
pmcid: 3721510
Zhu Y, Knolhoff BL, Meyer MA et al (2014) CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 74:5057–5070. https://doi.org/10.1158/0008-5472.CAN-13-3723
doi: 10.1158/0008-5472.CAN-13-3723
pubmed: 25082815
pmcid: 4182950
Strachan DC, Ruffell B, Oei Y et al (2013) CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 T cells CSF1R inhibition delays cervical and mammary tumor growth in murine models by. Oncoimmunology 2(12):e26968. https://doi.org/10.4161/onci.26968
doi: 10.4161/onci.26968
pubmed: 24498562
pmcid: 3902121
Garcia AJ, Ruscetti M, Arenzana TL, Tran LM, Bianci-frias D, Sybert E (2017) Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor. Mol Cell Biol 34(11):2017–2028. https://doi.org/10.1128/MCB.00090-14
doi: 10.1128/MCB.00090-14
Pasello G, Zago G, Lunardi F et al (2018) Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical–pathological features and intratumor heterogeneity over time original article. Ann Oncol 29(March):1258–1265. https://doi.org/10.1093/annonc/mdy086
doi: 10.1093/annonc/mdy086
pubmed: 29514216
Fassina A, Cappellesso R, Guzzardo V et al (2011) Epithelial–mesenchymal transition in malignant mesothelioma. Mod Pathol 25(1):86–99. https://doi.org/10.1038/modpathol.2011.144
doi: 10.1038/modpathol.2011.144
pubmed: 21983934
Hmeljak J, Sanchez-vega F, Hoadley KA et al (2018) Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov 81(12):1548–1565. https://doi.org/10.1158/2159-8290.CD-18-0804
doi: 10.1158/2159-8290.CD-18-0804
Mezzapelle R, Rrapaj E, Gatti E et al (2016) Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells. Sci Rep 6(February):22850. https://doi.org/10.1038/srep22850
doi: 10.1038/srep22850
pubmed: 26961782
pmcid: 4785401
Schwartz H, Blacher E, Amer M et al (2016) Incipient melanoma brain metastases instigate astrogliosis and neuroinflammation. Cancer Res 76(15):4359–4372. https://doi.org/10.1158/0008-5472.CAN-16-0485
doi: 10.1158/0008-5472.CAN-16-0485
pubmed: 27261506
Strachan DC, Ruffell B, Oei Y et al (2013) CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 T cells. Oncoimmunology 2(12):e26968. https://doi.org/10.4161/onci.26968
doi: 10.4161/onci.26968
pubmed: 24498562
pmcid: 3902121
Zhu Y, Knolhoff BL, Meyer MA et al (2014) CSF1/CSF1R blockade reprograms tumor-in filtrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 74:5057–5070. https://doi.org/10.1158/0008-5472.CAN-13-3723
doi: 10.1158/0008-5472.CAN-13-3723
pubmed: 25082815
pmcid: 4182950
Menon H, Ramapriyan R, Cushman TR et al (1933) Role of radiation therapy in modulation of the tumor stroma and microenvironment. Front Immunol 10(February):2019. https://doi.org/10.3389/fimmu.2019.00193
doi: 10.3389/fimmu.2019.00193
Bernstein MB, Krishnan S, Hodge JW, Chang JY (2016) Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol 13(8):516–524. https://doi.org/10.1038/nrclinonc.2016.30
doi: 10.1038/nrclinonc.2016.30
pubmed: 26951040
pmcid: 6053911
Yao ES, Zhang H, Chen Y et al (2007) Increased B1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res 67(2):659–665. https://doi.org/10.1158/0008-5472.CAN-06-2768
doi: 10.1158/0008-5472.CAN-06-2768
pubmed: 17234776
Hu-lieskovan S, Mok S, Moreno BH et al (2015) Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma. Sci Transl Med 7(279):279ra41
doi: 10.1126/scitranslmed.aaa4691
Frederick DT, Piris A, Cogdill AP et al (2013) BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 19(5):1225–1232. https://doi.org/10.1158/1078-0432.CCR-12-1630
doi: 10.1158/1078-0432.CCR-12-1630
pubmed: 23307859
pmcid: 3752683
Pelster MS, Amaria RN (2019) Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials. Ther Adv Med Oncol 11:1–11. https://doi.org/10.1177/1758835919830826
doi: 10.1177/1758835919830826
Morgan A, Holmes A (1980) Concentrations and dimensions of coated and uncoated asbestos fibres in the human lung. Br J Ind Med 37:25–32
pubmed: 7370190
pmcid: 1008641
Feder IS, Tischoff I, Theile A, Schmitz I, Merget R, Tannapfel A (2017) The asbestos fibre burden in human lungs: new insights into the chrysotile debate. Eur Respir J 49:1602534. https://doi.org/10.1183/13993003.02534-2016
doi: 10.1183/13993003.02534-2016
pubmed: 28663314
pmcid: 5898940
Boylan AM, Sanan DA, Sheppard D, Broaddus VC (1995) Vitronectin enhances internalization of crocidolite asbestos by rabbit pleural mesothelial cells via the integrin avfi5. J Cli Invest 96:1987–2001
doi: 10.1172/JCI118246
Liu W, Ernst JD, Broaddus VC (2000) Phagocytosis of crocidolite asbestos induces oxidative stress, DNA damage, and apoptosis in mesothelial cells. Am J Respir Cell Mol Biol 23:371–378
doi: 10.1165/ajrcmb.23.3.4094
Serio G, Pagliarulo V, Marzullo A, Punzi A, Pezzuto F (2016) Case report molecular changes of malignant mesothelioma in the testis and their impact on prognosis: analyses of two cases. Int J Clin Exp Pathol 9(7):7658–7667
Marsella JM, Liu BL, Vaslet CA, Kane AB (1997) Susceptibility of p53-deficient mice to induction of mesothelioma by crocidolite asbestos fibers. Environ Health Perspect 105(September):1069–1072
pubmed: 9400702
pmcid: 1470134
de Reynies A, Jaurand M-C, Renier A et al (2014) Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clin Cancer Res 20(5):1323–1335. https://doi.org/10.1158/1078-0432.CCR-13-2429
doi: 10.1158/1078-0432.CCR-13-2429
pubmed: 24443521
Chung CT, Da G, Santos C et al (2010) FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol 63:630–634. https://doi.org/10.1136/jcp.2010.076794
doi: 10.1136/jcp.2010.076794
pubmed: 20591913
pmcid: 2989172
Sarun KH, Lee K, Williams M et al (2018) Genomic deletion of BAP1 and CDKN2A are useful markers for quality control of malignant pleural mesothelioma (MPM) primary cultures. Int J Mol Sci 19:3056. https://doi.org/10.3390/ijms19103056
doi: 10.3390/ijms19103056
pmcid: 6213505
Hylebos M, Van Camp G, Van Meerbeeck JP (2016) The genetic landscape of malignant pleural mesothelioma: results from massively parallel sequencing. J Thorac Oncol 11(10):1615–1626. https://doi.org/10.1016/j.jtho.2016.05.020
doi: 10.1016/j.jtho.2016.05.020
pubmed: 27282309
Yamaguchi R, Perkins G (2012) Finding a panacea among combination cancer therapies. Cancer Res 72(1):18–23. https://doi.org/10.1158/0008-5472.CAN-11-3091
doi: 10.1158/0008-5472.CAN-11-3091
pubmed: 22052464
Bruno R, Alì G, Giannini R et al (2017) Malignant pleural mesothelioma and mesothelial hyperplasia: a new molecular tool for the differential diagnosis. Oncotarget 8(2):2758–2770
doi: 10.18632/oncotarget.13174
Parodi S, Filiberti R, Marroni P et al (2015) Differential diagnosis of pleural mesothelioma using logic learning machine. BMC Bioinformatics 16(Suppl 9):S3
doi: 10.1186/1471-2105-16-S9-S3
Tosun AB, Yergiyev O, Kolouri S, Silverman JF, Rohde GK (2015) Detection of malignant mesothelioma using nuclear structure of mesothelial cells in effusion cytology specimens. Cytometry A 87A:326–333. https://doi.org/10.1002/cyto.a.22602
doi: 10.1002/cyto.a.22602
Kundu S, Kolouri S, Erickson KI, Kramer AF, Rohde GK, May CV (2018) Discovery and visualization of structural biomarkers from MRI using transport-based morphometry. Neuroimage 167:256–275. arXiv:170504919v1
doi: 10.1016/j.neuroimage.2017.11.006
Dozier J, Zheng H, Adusumilli PS (2017) Immunotherapy for malignant pleural mesothelioma: current status and future directions. Trans Lung Cancer 6(4):315–324. https://doi.org/10.21037/tlcr.2017.05.02
doi: 10.21037/tlcr.2017.05.02
Milano MT, Zhang H (2010) Malignant pleural mesothelioma: a population-based study of survival. JTO Acquis 5(11):1841–1848. https://doi.org/10.1097/JTO.0b013e3181f1cf2b
doi: 10.1097/JTO.0b013e3181f1cf2b
Boutin C, Xey F, Gouvemet J et al (1993) Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients part 2: prognosis and staging. Cancer 72:394–404
doi: 10.1002/1097-0142(19930715)72:2<394::AID-CNCR2820720214>3.0.CO;2-5
Minnema-Luiting J, Vroman H, Aerts J, Cornelissen R (2018) Heterogeneity in immune cell content in malignant pleural mesothelioma. Int J Mol Sci 19:1041. https://doi.org/10.3390/ijms19041041
doi: 10.3390/ijms19041041
pmcid: 5979422
Varin E, Denoyelle C, Brotin E et al (2010) Downregulation of Bcl-x L and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy. Carcinogenesis 31(6):984–993. https://doi.org/10.1093/carcin/bgq026
doi: 10.1093/carcin/bgq026
pubmed: 20142415
Debrincat MA, Josefsson EC, James C et al (2012) Mcl-1 and Bcl-xL coordinately regulate megakaryocyte survival. Blood 119(24):5850–5858. https://doi.org/10.1182/blood-2011-12-398834
doi: 10.1182/blood-2011-12-398834
pubmed: 22374700
Yamaguchi R, Lartigue L, Perkins G (2019) Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy. Pharmacol Ther 195:13–20
doi: 10.1016/j.pharmthera.2018.10.009
Soini Y, Kinnula V, Kaarteenaho-wiik R, Apoptosis KE (1999) Expression of apoptosis regulating proteins bcl-2. Clin Cancer Res 5(November):3508–3515
pubmed: 10589765
Yamaguchi R, Perkins G, Hirota K (2015) Targeting cholesterol with beta-cyclodextrin sensitizes cancer cells for apoptosis. FEBS Lett 589:4097. https://doi.org/10.1016/j.febslet.2015.11.009
doi: 10.1016/j.febslet.2015.11.009
pubmed: 26606906